SpectRx seeks buyer for insulin pump infusion set unit
This article was originally published in The Gray Sheet
Executive Summary
Firm's SimpleChoice insulin pump infusion set business is up for sale as part of a broader SpectRx reorganization aimed at refocusing the company on its noninvasive LightTouch cervical cancer detection technology, including funding ongoing pivotal trials of the device, the firm says March 15. SpectRx also is seeking a partner for its development-stage continuous glucose monitoring technology. LightTouch, which uses light to scan the cervix for disease, is intended as a triage step for women with positive Pap smear or human papillomavirus (HPV) tests to confirm whether colposcopy and biopsy are warranted (1"The Gray Sheet" Sept. 18, 2006, In Brief)...
You may also be interested in...
SpectRx divests SimpleChoice
Firm sells insulin pump infusion set business to ICU Medical for undisclosed terms May 9. The move is part of SpectRx's plan to refocus on its noninvasive LightTouch cervical cancer detection business (1"The Gray Sheet" March 19, 2007, In Brief). ICU Medical introduced its own Orbit 90 diabetes infusion set in 2006...
SpectRx cervical cancer detection
Grant of $690,000 from the National Cancer Institute, announced Sept. 13, will go toward completing a pivotal trial for SpectRx' noninvasive LightTouch cervical cancer detection technology. More than 1,100 women have been enrolled in the five-site trial, expected to complete enrollment in 2007. The firm will seek expedited PMA approval of LightTouch as a triage step for women with positive Pap or HPV tests to confirm whether colposcopy and biopsy are warranted. SpectRx has received a total of $3.2 mil. in NCI funding for the product...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”